Brukinsa (Zanubrutinib)
- Medicine Name: Brukinsa
- Generic Name: Zanubrutinib
- Dosage Form & Strength: Capsules: 80 mg
- Manufactured By: BeiGene, Ltd.
- Brukinsa is a kinase inhibitor used for the treatment of adult patients with:
- Mantle cell lymphoma (MCL) who have received at least one prior therapy.
- Waldenström’s macroglobulinemia (WM).
- Relapsed/Refractory marginal zone lymphoma (MZL) who have taken at least single anti-CD20-based regimen.
Recommended Dosage: The recommended dosage of Brukinsa Capsules is 160 mg taken orally twice daily or 320 mg taken orally once daily until the disease is progressive or unacceptable toxicity occurs. Capsules can be taken with or without food. Swallow capsules whole with water. Do not open, break, or chew the capsules. If a dose is missed, it should be taken as soon as possible on the same day with a return to the normal schedule the following day.
- Fatal and severe hemorrhagic events have emerged in patients with hematological malignancies treated with zanubrutinib 80 mg monotherapy. Co-administration of zanubrutinib with antiplatelet or anticoagulant drugs may further increase the risk of hemorrhage. Monitor for signs/symptoms of bleeding.
- Fatal and severe infections (including bacterial, viral, or fungal) and opportunistic infections have emerged in patients with hematological malignancies treated with Zanubrutinib monotherapy. Monitor and assess patients for fever or other signs/symptoms of infection and treat them appropriately.
- Grade 3/4 cytopenias, including neutropenia (26%), thrombocytopenia (11%) and anemia (8%) on behalf of laboratory measurements, occurred in patients treated with zanubrutinib 80 mg capsule. Monitor complete blood counts on a regular basis during therapy and interrupt therapy, reduce the dose, or discontinue therapy as warranted.
- Second primary malignancies, including non-skin carcinoma, have emerged in patients treated with Brukinsa monotherapy. Patients should use sun protection and they should be monitored for the development of second primary malignancies.
- Atrial flutter and atrial fibrillation were reported in 3.2 percent of patients treated with Brukinsa 80 mg Capsules. Patients with hypertension, acute infections and cardiac risk factors may be at increased risk. Monitor signs/symptoms for atrial flutter and atrial fibrillation and manage as appropriate.
- On behalf of findings from animals, Zanubrutinib can cause fetal harm if used by a pregnant woman. Women should avoid becoming pregnant while taking Zanubrutinib and for 7 days after the final dose. Men should avoid fathering a child during treatment and for 7 days after the final dose.
What documents are required to import BRUKINSA to India?
BRUKINSA® (zanubrutinib) capsules can be imported by patients or government hospitals on the name of the patients only.
The following documentation required to import the product:
- Valid prescription from a qualified doctor.Patients diagnostic reports
- Patients id proof (issued by government of India)
How does order be confirmed?
The order will be confirmed only after the receipt of:
- Valid prescription of Doctor
- Import permit if applicable
Is BRUKINSA available in India?
BRUKINSA (zanubrutinib capsules) is a (prescription drug, prescription medication or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.
IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is facilitator providing input
On availability of Brukinsa in India (Mumbai, Pune, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, and Bangalore etc.)
- Medicine Price.
- Finding Genuine and reliable source from Canada, Europe, USA and Australia
- Ensuring 100% transparency.
BRUKINSA can be made available to patients, doctors and hospitals at Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow and Pune and other cities in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and import permit.
IPN (Indian Pharma Network) can facilitate the supply of BRUKINSA (prescription medicines) to all locations in the world and in India after fulfilling the legal requirement (if applicable)
Please contact +91-9310090915 | Toll-Free No: 1800-889-1064 or write us at info@indianpharmanetwork.in for Brukinsa 80 mg Capsules price in India.
We take guarantee of quality and delivery anywhere in the world as per the buyer’s requirements.
Indian Pharma Network is able to source BRUKINSA (Cancer Treatment Medicines) from across the globe, and has the ability to supply. Indian Pharma offers its customers worldwide access to the best available treatment.
Indian Pharma Network is able to dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient’s address only from New Delhi, India.
What is the Generic Name for the trade name drug Brukinsa®?
Zanubrutinib is Generic Name for the trade name drug Brukinsa®.
What is the Manufacturer Name of Brukinsa®?
Brukinsa® is manufactured by BeiGene, Ltd.
Is Brukinsa® approved by the FDA?
Yes, Brukinsa® is approved by the FDA. Date of approval: November 14, 2019.
Is Brukinsa® chemotherapy?
Brukinsa® (Zanubrutinib) is a Chemotherapy Regimen for Lymphoma, Mantle Cell.
Does Brukinsa® cause high blood pressure?
Yes, Brukinsa may raise your blood pressure. Check your blood pressure on a regular basis and tell your health specialist in case the results are high.
What are the most common side effects due to Brukinsa®?
Most common side effects due to Brukinsa® include: rash, neutrophil count decreased, hemorrhage, platelet count decreased, upper respiratory tract infection, lymphocyte count decreased, and musculoskeletal pain.
How much does Zanubrutinib cost in India?
Zanubrutinib cost in India is reasonable and can vary. To procure this kinase inhibitor authentically, you can call or WhatsApp +91-9310090915 or send mail to info@indianpharmanetwork.in.
What are the storage conditions of Brukinsa®?
Store the capsules Brukinsa at 20 to 25°C (68 to 77°F); excursions permitted between 15 to 30°C (59 to 86°F).
Is it safe to buy Brukinsa® online in India?
Yes, You can buy Brukinsa capsules online in India legitimately from https://www.indianpharmanetwork.in/ if this drug has not been approved or is not available in your country.
Is Indian Pharma Network certified by WHO-GDP and ISO 9001:2008 authorities?
Yes, We have certification from the highest authorities like WHO-GDP and ISO 9001:2008. We’re leading Supplier and Wholesaler of Brukinsa in India. We can help you to get this medicine at the lowest affordable cost.
What are the Highlights of prescribing information for Brukinsa®?
Click Here to download full Brukinsa prescribing information.
Contact Patient Support
If you have any questions or need any help, contact our Patient Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.
Disclaimer
CMV retinitis is kind of an eye infection caused by a virus. CMV mainly attacks the retina of the eye and can be responsible for causing loss of vision, and eventually may lead to the blindness. Patients with acquired immunodeficiency syndrome are more likely to develop CMV retinitis. CMV retinitis is kind of an eye infection caused by a virus. CMV mainly attacks the retina of the eye and can be responsible for causing loss of vision, and eventually may lead to the blindness. Patients with acquired immunodeficiency syndrome are more likely to develop CMV retinitis.